Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Wall Street's sentiment toward Bio-Techne Corporation (TECH) stock remains divided. While the company has outperformed the broader market on a year-to-date basis, its growth has been overshadowed by the iShares Biotechnology ETF (IBB) over the same period. TECH's financial performance has been mixed, with steady bottom-line net income growth but sluggish top-line revenue expansion. However, cost controls and operational efficiencies have improved GAAP operating margins and net earnings.

Despite these positive indicators, TECH's stock has underperformed compared to the iShares Biotechnology ETF. The company reported mixed Q4 results, with revenue exceeding expectations but failing to match analysts' forecasts. For the fiscal year 2027, analysts predict a modest growth in EPS. The consensus rating stands at a Hold, with one Strong Buy rating, 13 Holds, and one Strong Sell rating from the 15 analysts covering the stock.

Wells Fargo & Company recently downgraded TECH to an Equal Weight rating with a $73 price target. Nevertheless, TECH currently trades above its mean price target, suggesting market optimism.